By Paolo Aloisi M.D., Francesco Martella Ph.D. (auth.), Mauro Bologna (eds.)
Biotargets of melanoma in present scientific Practice provides an up-to-date and reasoned assessment of the present prestige of data about the significant melanoma varieties with a distinct concentrate on the present biomarkers, genes concerned and the capability destiny pursuits of cutting edge remedies. the amount comprises for every significant melanoma style, a finished even though concise dialogue of epidemiology, affirmed and leading edge biomarkers for prognosis, and outlines of the correct genes for diagnosis and (individualized) remedy via biotarget-specific new molecular remedies, with the newest details at the validation prestige of every novel biomarker. person chapters are devoted to the most important melanoma varieties, plus a different bankruptcy on metastasis. the current debate on patentability of genetic info utilized to diagnostics and therapeutics of melanoma is additionally discussed.
Read or Download Biotargets of Cancer in Current Clinical Practice PDF
Similar cancer books
Cancer Cell Culture: Methods and Protocols
With many contemporary advances, melanoma cellphone tradition study is extra vital than ever ahead of. This well timed version of melanoma telephone tradition: tools and Protocols covers the elemental strategies of melanoma mobile biology and tradition whereas increasing upon the hot shift in phone tradition equipment from the new release of recent telephone traces to using basic cells.
Die tierische Zelle in Zellkultur
Die ersten erfolgreichen Versuche zur Züchtung tierischer Zellen außerhalb des Organismus reichen zurück in den Beginn unseres Jahrhunderts. 1907 gelang HARRI SON durch Explantation von Gewebsstücken aus Froschembryonen der Nachweis, daß in der Embryonalentwicklung die Neuriten als Fortsätze der Nervenzelle ohne Be teiligung anderer Zellen gebildet werden, und daß damit eine spezifische celluläre Funktion auch außerhalb des Gesamtorganismus zu beobachten ist [310,311].
Port-Site and Wound Recurrences in Cancer Surgery: Incidence - Pathogenesis - Prevention
Up to now nine years, experiences of 'port-site' deposits following laparoscopic surgical procedure for malignancy, in particular laparoscopic resection of colonic melanoma, have forged a shadow at the knowledge of the laparoscopic strategy within the surgical guy agement in sufferers with melanoma. these studies of port-site deposits, a few ninety circumstances said within the literature as much as 1999, have opened a 'can of worms' and highlighted the shortage of our wisdom on melanoma telephone migration from strong tu mors and the standards that underlie their profitable implantation in surgical wounds either within the presence and lack of a good strain pneumoperito neum.
- Cancer and Sexual Health
- Breast cancer genes and the gendering of knowledge : science and citizenship in the cultural context of the "new" genetics
- Novel Biomarkers in the Continuum of Breast Cancer
- Anticancer: A New Way of Life
- Breast Reconstruction with Autologous Tissue Art and Artistry
- Nanoscale Insights into Ion-Beam Cancer Therapy
Additional info for Biotargets of Cancer in Current Clinical Practice
Example text
18 63. Yaman E, et al. Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. Onkologie. 2008;31:309–13. 64. Batchelor TT, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95. 65. Vredenburgh JJ, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253–9.
Phase II trial of temsirolimus (CCI779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294–304. 70. Chang SM, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357–61. 71. Cloughesy TF, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
2005;352(10):997–1003. 54. Rich JN, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133–42. 55. Franceschi E, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96:1047–51. 56. Krishnan S, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.